These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 21388324)

  • 1. Adjuvant docetaxel for node-negative breast cancer.
    Venniyoor A
    N Engl J Med; 2011 Mar; 364(10):976-7; author reply 977-8. PubMed ID: 21388324
    [No Abstract]   [Full Text] [Related]  

  • 2. Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer.
    Martin M; Vogel C; Crown J; Mackey J
    JAMA; 2005 Nov; 294(17):2166; author reply 2166-7. PubMed ID: 16264153
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant trastuzumab with docetaxel or vinorelbine for HER-2-positive breast cancer.
    Ferretti G; Papaldo P; Fabi A; Carlini P; Felici A; Cognetti F
    Oncologist; 2006; 11(7):853-4. PubMed ID: 16880245
    [No Abstract]   [Full Text] [Related]  

  • 4. Mechanisms of stimulation of granulocytopoiesis with neupogen in patients with breast cancer during chemotherapy.
    Khrichkova TY; Gol'dberg VE; Zhdanov VV; Matyash MG; Vysotckaya VV; Simolina EI; Shatalova VA; Popova NO; Miroshnichenko LA; Dygai AM
    Bull Exp Biol Med; 2008 Apr; 145(4):467-71. PubMed ID: 19110596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant docetaxel for high-risk, node-negative breast cancer.
    Martín M; Seguí MA; Antón A; Ruiz A; Ramos M; Adrover E; Aranda I; Rodríguez-Lescure A; Grosse R; Calvo L; Barnadas A; Isla D; Martinez del Prado P; Ruiz Borrego M; Zaluski J; Arcusa A; Muñoz M; López Vega JM; Mel JR; Munarriz B; Llorca C; Jara C; Alba E; Florián J; Li J; López García-Asenjo JA; Sáez A; Rios MJ; Almenar S; Peiró G; Lluch A;
    N Engl J Med; 2010 Dec; 363(23):2200-10. PubMed ID: 21121833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 testing in patients with breast cancer.
    Dixon JM; Wilson V; Verrill M; Symmans WF
    BMJ; 2012 Jun; 344():e3958. PubMed ID: 22689887
    [No Abstract]   [Full Text] [Related]  

  • 7. [AIOM Conference 2004. Docetaxel: a recent conquest in the adjuvant therapy of breast cancer].
    Adamo V
    Tumori; 2004; 90(6):13-21. PubMed ID: 15762373
    [No Abstract]   [Full Text] [Related]  

  • 8. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
    Steger GG; Galid A; Gnant M; Mlineritsch B; Lang A; Tausch C; Rudas M; Greil R; Wenzel C; Singer CF; Haid A; Pöstlberger S; Samonigg H; Luschin-Ebengreuth G; Kwasny W; Klug E; Kubista E; Menzel C; Jakesz R;
    J Clin Oncol; 2007 May; 25(15):2012-8. PubMed ID: 17513805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy with TAC (docetaxel, doxorubicin, and cyclophosphamide) in patients with breast cancer--incidence of neutropenic fever outside clinical trials.
    Passos-Coelho JL; Esteves S; Vieira PA; Isidoro M; Ribeiro M; Oliveira J; Moreira AR
    Breast J; 2011; 17(5):539-41. PubMed ID: 21899649
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant docetaxel for node-negative breast cancer.
    Sanz A; del Valle ML
    N Engl J Med; 2011 Mar; 364(10):977; author reply 977-8. PubMed ID: 21388323
    [No Abstract]   [Full Text] [Related]  

  • 11. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
    Wolowacz SE; Cameron DA; Tate HC; Bagust A
    J Clin Oncol; 2008 Feb; 26(6):925-33. PubMed ID: 18281666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy in older women with breast cancer: who and what?
    Muss HB
    J Clin Oncol; 2014 Jul; 32(19):1996-2000. PubMed ID: 24868030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel and adjuvant treatment of breast cancer.
    Prescrire Int; 2011 Jun; 20(117):149. PubMed ID: 21678701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for breast cancer.
    Livi L; Meattini I; de Luca Cardillo C; Scotti V; Agresti B; Franzese C; Sanchez L; Nori J; Bertocci S; Cassani S; Bianchi S; Cataliotti L; Biti G
    J Chemother; 2011 Feb; 23(1):36-9. PubMed ID: 21482493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.
    Bonnefoi H; Zaman K; Debled M; Fiche M; Fournier M; Nobahar M; Pierga JY; Koch KM; Bartlett J; Zimmer A; Marreaud S; Bogaerts J; Cameron D
    Eur J Cancer; 2013 Jan; 49(2):281-9. PubMed ID: 22999386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How should we prescribe lapatinib to our patients: once daily or twice daily, and at what dose?
    Ciccarese M; Lorusso V
    J Clin Oncol; 2009 Jan; 27(2):314-5; author reply 315-7. PubMed ID: 19064955
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor.
    Kornek GV; Ulrich-Pur H; Penz M; Haider K; Kwasny W; Depisch D; Kovats E; Lang F; Schneeweiss B; Scheithauer W
    J Clin Oncol; 2001 Feb; 19(3):621-7. PubMed ID: 11157011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    J Clin Oncol; 2007 Apr; 25(10):1232-8. PubMed ID: 17296975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
    J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.